Last Price$104.91.0%
Market Cap$154.5B
17.6%
Peers median - 3.1%
14.6%
Peers median - 15.3%
50.7%
Peers median - 29.9%
8.0%
Peers median - 14.4%
Competing with BSX
Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name | Market Cap | Quality rating | Intrinsic value | 1Y Return | Revenue | Free Cash Flow | Revenue growth | FCF margin | Gross margin | ROIC | Total Debt to Equity |
$154.5B | 6.7 | $34.2 67.4% overvalued | 55.5% | $16.7B | $2,438.0M | 17.6% | 14.6% | 67.0% | 8.0% | 50.7% | |
$242.4B | 7.0 | $174.5 24.5% undervalued | 19.2% | $42.0B | $6,351.0M | 4.6% | 15.1% | 55.6% | 25.3% | 31.4% | |
$150.5B | 6.6 | $305.1 22.7% overvalued | 12.0% | $22.6B | $3,487.0M | 10.2% | 15.4% | 62.8% | 14.6% | 28.4% | |
$120.9B | 6.2 | $114.6 21.5% undervalued | 14.7% | $33.2B | $5,467.0M | 2.7% | 16.5% | 52.7% | 7.4% | 53.6% | |
$43.4B | 6.1 | $54.1 24.2% overvalued | (18.0%) | $5,872.6M | $502.2M | 0.9% | 8.6% | 77.8% | 25.8% | 7.4% | |
$34.9B | 7.0 | $43.1 49.8% overvalued | (29.7%) | $4,033.0M | $453.9M | 11.3% | 11.3% | 60.4% | 21.7% | 120.3% | |
$24.7B | 5.3 | $65.0 146.8% undervalued | 34.0% | €18.0B | €274.0M | (0.8%) | 1.5% | 43.1% | (4.2%) | 63.4% | |
$21.9B | 6.2 | $199.6 10.4% overvalued | (3.8%) | $5,398.4M | $751.4M | (0.2%) | 13.9% | 44.7% | 8.2% | 1.9% | |
$21.6B | 5.9 | $181.2 72.0% undervalued | (15.3%) | $5,655.4M | $1,132.4M | (23.5%) | 20.0% | 64.3% | 4.5% | 43.0% | |
$19.4B | 7.9 | $134.5 50.7% overvalued | 62.5% | $1,900.3M | $303.0M | 12.0% | 15.9% | 76.4% | 29.7% | 6.9% | |
$13.6B | 6.0 | $190.0 8.5% undervalued | (43.2%) | $3,999.0M | $622.7M | 3.5% | 15.6% | 70.3% | 14.2% | 2.3% |
Compare BSX Valuation Multiples with Peers
LTM
NTM
1Y Forward
2Y Forward
EV/Revenue
General
Valuation Multiple
Financial metrics
Company name
EV/Revenue
Revenue growth
EBITDA margin
Net Income margin
Boston Scientific CorporationBSX
9.9x
17.6%
16.7%
11.1%
Median Peer Set
5.4x
4.1%
126.3%
12.7%
Abbott LaboratoriesABT
5.9x
4.6%
134.5%
31.9%
Align Technology, Inc.ALGN
3.2x
3.4%
26.0%
11.5%
DexCom, Inc.DXCM
8.6x
11.3%
(1.4%)
14.3%
Edwards Lifesciences CorporationEW
6.8x
(9.4%)
202.2%
76.7%
Medtronic plcMDT
4.4x
3.6%
(2.1%)
11.4%
Koninklijke Philips N.V.PHG
1.6x
(0.8%)
118.1%
(3.9%)
Insulet CorporationPODD
9.7x
30.0%
4,364.6%
12.2%
STERIS plcSTE
4.1x
3.6%
257.9%
7.4%
Stryker CorporationSYK
7.0x
10.2%
(5.8%)
13.2%
Zimmer Biomet Holdings, Inc.ZBH
4.8x
6.5%
253.2%
13.8%
Compare BSX Valuation Multiples Dynamics with Peers
Crunching data... Almost there!
FAQ
1. How does Boston Scientific Corporation (BSX) revenue growth compare to peers and the industry?
Boston Scientific Corporation (BSX) revenue growth is 17.6%, compared to the peers' median of 3.1%.
2. How does Boston Scientific Corporation (BSX) Free Cash Flow (FCF) margin compare to peers and the industry?
Boston Scientific Corporation (BSX) FCF margin is 14.6%, compared to the peers' median of 15.3%.
3. How does Boston Scientific Corporation (BSX) Total Debt to Equity ratio compare to peers and the industry?
Boston Scientific Corporation (BSX) Total Debt to Equity ratio is 50.7%, compared to the peers' median of 29.9%.
4. How does Boston Scientific Corporation (BSX) ROIC (Return on Invested Capital) compare to peers and the industry?
Boston Scientific Corporation (BSX) ROIC is 8.0%, compared to the peers' median of 14.4%.